1. Home
  2. NBN vs AKBA Comparison

NBN vs AKBA Comparison

Compare NBN & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northeast Bank

NBN

Northeast Bank

HOLD

Current Price

$106.26

Market Cap

836.7M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.42

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBN
AKBA
Founded
1872
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
836.7M
729.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NBN
AKBA
Price
$106.26
$1.42
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$117.50
$5.75
AVG Volume (30 Days)
84.5K
2.5M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
0.04%
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.77
N/A
Revenue Next Year
$18.72
N/A
P/E Ratio
$11.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$78.17
$1.14
52 Week High
$126.26
$4.08

Technical Indicators

Market Signals
Indicator
NBN
AKBA
Relative Strength Index (RSI) 37.72 52.20
Support Level $104.20 $1.30
Resistance Level $112.26 $1.52
Average True Range (ATR) 3.58 0.07
MACD -0.25 0.02
Stochastic Oscillator 24.67 56.58

Price Performance

Historical Comparison
NBN
AKBA

About NBN Northeast Bank

Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: